International Journal of Drug Policy
Volume 21, Issue 2 , Pages 122-124, March 2010

Methadone as HIV prevention: High Volume Methadone Sites to decrease HIV incidence rates in resource limited settings

Yale University, School of Medicine, AIDS Programme, 135 College Street, Suite 323, New Haven, CT 06510, United States

Received 30 September 2009; received in revised form 12 October 2009; accepted 14 October 2009. published online 20 November 2009.

Abstract 

The link between injection drug use and HIV has been extensively described. Despite worldwide prevention efforts, injection drug use continues to be a risk factor for HIV transmission and both HIV and injection drug use continues to spread across the globe. Although methadone has demonstrated multiple health benefits including the reduction in injection drug use and HIV acquisition, the utilisation of methadone in many areas of the world remains one of secondary, rather than primary, HIV prevention. As a result, many who finally begin methadone enter treatment having accumulated medical and mental health problems as a result of delayed treatment. Rapid access to treatment and a more aggressive policy that realizes that methadone can help reduce opioid drug use is necessary if methadone is effectively going to act as primary HIV prevention. To delay access to methadone only increases the probability that the individual will acquire an infectious disease that is more costly to the individual in terms of morbidity and mortality and more costly to society as a whole.

Keywords: HIV prevention, Methadone, Opioid dependence, Injection drug use

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0955-3959(09)00130-3

doi:10.1016/j.drugpo.2009.10.004

International Journal of Drug Policy
Volume 21, Issue 2 , Pages 122-124, March 2010